Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Reverse Split !!!
View:
Post by Jumpinjackfast on Oct 28, 2021 3:43pm

Reverse Split !!!

Don't do it at 30 to 60 for 1 way , way to aggressive , going forward the long time shareholders are getting wronged on this , this share problem was nothing but MANAGEMENT'S fault only thing there ever accomplished was capital destruction since there quick sale scheme 3 yrs. back always Partnership and it was those 2 greed consumed individuals . They need 10 to 15 split at best if they had some great news coming or revenue they wouldn't be asking for such a chopping , they need Non Dillutive capital backing , then they can raise capital at fair price it's the only way to preserve shareholder value , if that matters . What a scheme it's the shareholders fault we failed to partner on the ALS, PD .
Comment by Thenorth1990 on Oct 28, 2021 4:11pm
Fully agree with you , but that's what we sign up for when we invest with a company with no cash flows in the past nor in the near future(Serology revenue will be peanuts) may be the risk will pay off in future. Acumen after their ipo is down around 30% .. but their market cap is much higher. May be we will get there after all this nasdaq stuff, definitely not just with retail Investors
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities